ICU Medical raises FY24 EPS view to $5.40-$5.70 from $4.95-$5.35

Consensus $ $5.22. Narrows FY24 adjusted EBITDA view to $355M-$365M from $345M-$365M. The company said, “For Fiscal Year 2024 the Company updated its estimates of GAAP net loss from a range of $(118) to $(108) to a range of $(130) to $(122) and GAAP diluted loss per share from a range of $(4.78) to $(4.38) to a range of $(5.28) to $(4.98). The Company updated the estimated range of its full year 2024 guidance of adjusted EBITDA from a range of $345 million to $365 million to a range of $355 million to $365 million and updated the estimated range of diluted earnings per share from a range of $4.95 to $5.35 to a range of $5.40 to $5.70.”